Bayer to license lipid-nanoparticle tech from Acuitas

2023-06-07

疫苗信使RNA基因疗法引进/卖出

Bayer, looking to enhance its gene editing program, will partner with Acuitas Therapeutics on the development of lipid-nanoparticle systems for molecular therapeutics.

Canada-based Acuitas' clinically validated LNP delivery technology enables the targeted delivery of ribonucleic acids (RNA) to the liver. The proprietary technology was also used to develop the Pfizer-BioNTech COVID-19 vaccine COVID-19 vaccine.

In addition to mRNA, Acuitas Acuitas' LNP can be used to deliver a range of different nucleic acid therapeutics including small interfering RNA (siRNA), antisense oligonucleotides and DNA.

Bayer, through its gene therapy unit, AskBio, hopes that the partnership will help accelerate its first in vivo gene editing programs to the clinic. Bayer paid $2 billion upfront back in 2020 in a deal that focused on AskBio’s industry-leading AAV-based gene therapy platform.

Financial details of the Acuitas deal were not disclosed.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构